These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35439421)

  • 1. The Ascension of Targeted Covalent Inhibitors.
    Singh J
    J Med Chem; 2022 Apr; 65(8):5886-5901. PubMed ID: 35439421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Covalent Inhibitors for Drug Design.
    Baillie TA
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13408-13421. PubMed ID: 27539547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors.
    Kreamer K; Riordan D
    Clin J Oncol Nurs; 2015 Dec; 19(6):734-42. PubMed ID: 26583637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted covalent drugs of the kinase family.
    Singh J; Petter RC; Kluge AF
    Curr Opin Chem Biol; 2010 Aug; 14(4):475-80. PubMed ID: 20609616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
    Basu D; Richters A; Rauh D
    Bioorg Med Chem; 2015 Jun; 23(12):2767-80. PubMed ID: 25975640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets.
    Lee J; Park SB
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent vs. Non-Covalent Inhibition: Tackling Drug Resistance in EGFR - A Thorough Dynamic Perspective.
    Akher FB; Farrokhzadeh A; Soliman MES
    Chem Biodivers; 2019 Mar; 16(3):e1800518. PubMed ID: 30548188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
    Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
    J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in covalent kinase inhibitors.
    Abdeldayem A; Raouf YS; Constantinescu SN; Moriggl R; Gunning PT
    Chem Soc Rev; 2020 May; 49(9):2617-2687. PubMed ID: 32227030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinases inhibitors in lung cancer: From benchside to bedside.
    Singh PK; Singh H; Silakari O
    Biochim Biophys Acta; 2016 Aug; 1866(1):128-40. PubMed ID: 27393082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cysteinome of Protein Kinases as a Target in Drug Development.
    Chaikuad A; Koch P; Laufer SA; Knapp S
    Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.